Aeterna Zentaris has expanded its existing research programme with the Julius-Maximilians-University Wuerzburg (JMU) to accelerate the development of Chlamydia trachomatis and Covid-19 vaccines.
Under the expanded deal, the human three-dimensional (3D) intestinal tissue models will be developed to study infection biology in the Salmonella primary action site.
The new method is expected to generate predictive and relevant additional data for the regulatory process.
The company’s vaccine technology aims to induce mucosal immunity for preventing infections.
It is intended to use two antigens to provide protection against escape mutants of the pathogens.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSee Also:
Aeterna Zentaris CEO Dr Klaus Paulini said: “As coordinator of the Graduate College ‘3D Infect’, funded by the German Research Foundation, Prof Rudel’s experience speaks for itself and we believe that will be a tremendous asset to our efforts.
“He is already involved in the Inno4vac project supported by the European Innovative Medicines Initiative 2, focused on the design and application of advanced predictive human models for the development of vaccines.”
The company has also signed a research deal with JMU for supplementary research activities and pre-clinical development studies of the potential vaccines, which are covered in the license agreements.
Aeterna signed a licence agreement with JMU in March last year.
Under the deal, the company gained an exclusive, global licence to certain patent applications owned by JMU for the research, development, manufacturing and commercialisation of a Covid-19 vaccine.
At present, pre-clinical studies are underway for the company’s vaccine platform to prevent Covid-19.
In September last year, the company used its option under the deal with JMU for chlamydia, a second indication.
